236 related articles for article (PubMed ID: 17196564)
1. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Rose S; Ramsay Croft N; Jenner P
Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
[TBL] [Abstract][Full Text] [Related]
3. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
4. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
6. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Stasi MA; Minetti P; Lombardo K; Riccioni T; Caprioli A; Vertechy M; Di Serio S; Pace S; Borsini F
Eur J Pharmacol; 2015 Aug; 761():353-61. PubMed ID: 25936513
[TBL] [Abstract][Full Text] [Related]
7. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
Lane EL; Cheetham SC; Jenner P
Exp Neurol; 2006 Feb; 197(2):284-90. PubMed ID: 16005456
[TBL] [Abstract][Full Text] [Related]
8. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
9. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
10. Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.
Lane EL; Cheetham SC; Jenner P
Eur J Neurosci; 2005 Jan; 21(1):179-86. PubMed ID: 15654855
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Pinna A; Pontis S; Borsini F; Morelli M
Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Tomiyama M; Kimura T; Maeda T; Tanaka H; Kannari K; Baba M
Synapse; 2004 Jun; 52(3):218-22. PubMed ID: 15065221
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Carta AR; Pinna A; Cauli O; Morelli M
Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
[TBL] [Abstract][Full Text] [Related]
15. In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Sarre S; Lanza M; Makovec F; Artusi R; Caselli G; Michotte Y
Eur J Pharmacol; 2008 Apr; 584(2-3):297-305. PubMed ID: 18342306
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
Wardas J
Pol J Pharmacol; 2003; 55(2):155-64. PubMed ID: 12926542
[TBL] [Abstract][Full Text] [Related]
17. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M
Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359
[TBL] [Abstract][Full Text] [Related]
18. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Kääriäinen TM; García-Horsman JA; Piltonen M; Männistö PT
Neuroreport; 2009 Feb; 20(3):313-8. PubMed ID: 19188858
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
[TBL] [Abstract][Full Text] [Related]
20. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Huang YX; Luo WF; Li D; Hu WD; Liu CF
Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
